脓毒症病人血清中Prdx1和Prdx6水平变化及临床意义

Change and clinical significance of the serum levels of Prdx1 and Prdx6 in sepsis patients

目的:探讨过氧化物酶(Prdx)1和Prdx6在脓毒症病人血清中表达水平和变化规律,以及其相关临床意义。方法:选取脓毒症病人共55例,采用酶联免疫吸附法检测入组病人第1、3、5、7天静脉血Prdx1和Prdx6表达水平,并收集相应时间的体温、白细胞计数、血小板、丙氨酸氨基转移酶、肌酐、降钙素原、C反应蛋白、急性生理与慢性健康评分、序贯器官衰竭评分,以及病人一般资料(性别、年龄、原发病、感染部位、感染细菌、有无使用去甲肾上腺素或机械通气)。结果:脓毒症休克病人血清中Prdx1水平高于脓毒症病人(P<0.05),2组血清中Prdx6水平差异无统计学意义(P>0.05);APACHEⅡ评分≥15分组脓毒症病人血清中Prdx1水平明显高于<15分组(P<0.01),而2组血清中Prdx6水平差异无统计学意义(P>0.05);第1、3、5和7天,存活组Prdx1水平随时间推移明显低于死亡组(P<0.01),除第3天外,2组血清Prdx6水平随时间推移差异无统计学意义(P>0.05)。结论:Prdx1和Prdx6在脓毒症病人血清中表达增高,两者可能成为脓毒症病人早期诊断和治疗的分子靶点。

Objective:To investigate the changes of serum levels of Prdx1 and Prdx6 in sepsis patients and their clinical significance.Methods:The serum levels of Prdx1 and Prdx6 in 55 patients with sepsis were determined by ELISA on the 1st,3rd,5th and 7th days of admission.The temperature,white blood cell count,platelet,alanine transaminase,creatinine,procalcitonin,C-reactive protein,scores of acute physiology and chronic health evaluation and sequential organ failure assessment and general data(gender,age,protopathy,infection site,pathogenic bacteria,norepinephrine use or mechanical ventilation)in all patients were analyzed at each point.Results:The serum level of Prdx1 in septic shock patients was higher than that in sepsis patients(P<0.05).There was no statistical significance in serum level of Prdx6 between two groups(P>0.05).The serum level of Prdx1 in patients with APACHEⅡscore≥15 was significantly higher than that in patients with APACHEⅡscore<15(P<0.01),the difference of the serum level of Prdx6 between two groups was not statistically significant(P>0.05).The serum levels of Prdx1 in survival group on the 1st,3rd,5th and 7th days were significantly lower than that in death group at time passed(P<0.01),and except the third day,the difference of the serum level of Prdx6 between two groups was not statistical significance(P>0.05).Conclusions:The serum levels of Prdx1 and Prdx6 in sepsis patients increase,which may become the molecular targets in the early diagnosis and treatment of sepsis.